aTyr Pharma
ATYR
90 hedge funds and large institutions have $23.2M invested in aTyr Pharma in 2026 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 30 reducing their positions, and 35 closing their positions.
321% more call options, than puts
Call options by funds: $573K | Put options by funds: $136K
3% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 30
17.55% less ownership
Funds ownership: 57.17% → 39.62% (-18%)
19% less funds holding
Funds holding: 111 → 90 (-21)
47% less capital invested
Capital invested by funds: $43.7M → $23.2M (-$20.5M)
54% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.38M |
| 2 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
+$1.17M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.16M |
| 4 |
Jane Street
New York
|
+$1.09M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$780K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.99M |
| 2 |
BlackRock
New York
|
-$3.02M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.53M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.31M |
| 5 |
State Street
Boston,
Massachusetts
|
-$823K |
ATYR Hedge Fund Activity: Q2 2026 in Review
90 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2026, worth a combined $23.2M — down 47% from $43.7M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ATYR and 16 opened new positions — a net loss of 19 holders — while 30 trimmed existing stakes and 29 added.
The largest buyer was AQR Capital Management, adding an estimated $1.38M. The largest seller was Fidelity Investments, cutting an estimated $7.99M.
- 90 institutional investors held aTyr Pharma (ATYR) as of Q2 2026, down from 111 in Q1 2026.
- Funds reported $23.2M of aTyr Pharma stock for Q2 2026, down 47% quarter-over-quarter.
- 16 funds opened new aTyr Pharma positions in Q2 2026 and 35 closed out, a net change of -19 holders.
- The largest aTyr Pharma buyer in Q2 2026 was AQR Capital Management, an estimated $1.38M added.
- The largest aTyr Pharma seller in Q2 2026 was Fidelity Investments, an estimated $7.99M sold.
Based on aggregated 13F filings for Q2 2026.